A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Subjects With Hepatitis C Infection
Phase of Trial: Phase I
Latest Information Update: 17 Jun 2015
Price : $35 *
At a glance
- Drugs MK 2248 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 19 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 15 Oct 2014 Planned End Date changed from 1 Feb 2015 to 1 Oct 2014 according to ClinicalTrials.gov record.
- 15 Oct 2014 Planned primary completion date changed from 1 Feb 2015 to 1 Oct 2014 according to ClinicalTrials.gov record.